Guide Management of Nonalcoholic Fatty Liver Disease

July 2022

You’ll see more focus on managing nonalcoholic fatty liver disease (NAFLD)...partly due to new guidelines.

It’s being called a “sleeper epidemic.” About 1 in 4 patients have this steatosis...but most don’t have symptoms.

NAFLD often goes hand in hand with CV risk factors, such as insulin resistance or diabetes...obesity...and dyslipidemia.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote